AU2005245918A1 - Interferon-alpha polypeptides and conjugates - Google Patents

Interferon-alpha polypeptides and conjugates Download PDF

Info

Publication number
AU2005245918A1
AU2005245918A1 AU2005245918A AU2005245918A AU2005245918A1 AU 2005245918 A1 AU2005245918 A1 AU 2005245918A1 AU 2005245918 A AU2005245918 A AU 2005245918A AU 2005245918 A AU2005245918 A AU 2005245918A AU 2005245918 A1 AU2005245918 A1 AU 2005245918A1
Authority
AU
Australia
Prior art keywords
polypeptide
seq
amino acid
sequence
acid positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005245918A
Other languages
English (en)
Inventor
Markus Dembowski
Roberto Falkenstein
Stephan Fischer
Adelbert Grossmann
Friederike Hesse
Hans Koll
Harald Kropshofer
Torben Lauesgaard Nissen
Phillip A. Patten
Andreas Schaubmar
Ralf Schumacher
Stefan Seeber
Sridhar Viswanathan
Anne Vogt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Maxygen Inc
Original Assignee
F Hoffmann La Roche AG
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Maxygen Inc filed Critical F Hoffmann La Roche AG
Publication of AU2005245918A1 publication Critical patent/AU2005245918A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2005245918A 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates Abandoned AU2005245918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19
US60/572,504 2004-05-19
PCT/US2005/017471 WO2005113592A2 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
AU2005245918A1 true AU2005245918A1 (en) 2005-12-01

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005245918A Abandoned AU2005245918A1 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Country Status (14)

Country Link
US (9) US7318918B2 (enExample)
EP (1) EP1753779A2 (enExample)
JP (1) JP2008507298A (enExample)
CN (1) CN101115769A (enExample)
AR (1) AR049177A1 (enExample)
AU (1) AU2005245918A1 (enExample)
BR (1) BRPI0511196A (enExample)
CA (1) CA2566247A1 (enExample)
IL (1) IL178470A0 (enExample)
MX (1) MXPA06013412A (enExample)
NO (1) NO20065084L (enExample)
RU (1) RU2006145020A (enExample)
TW (1) TW200611910A (enExample)
WO (1) WO2005113592A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
WO2000040715A2 (en) 1999-01-05 2000-07-13 Trustees Of Boston University Improved nucleic acid cloning
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
ES2585353T3 (es) * 2004-05-12 2016-10-05 Synchronoss Technologies, Inc. Sistema de identificación de contactos avanzado
US7485423B2 (en) 2004-11-11 2009-02-03 Modular Genetics, Inc. Ladder assembly and system for generating diversity
AU2006257286B2 (en) * 2005-03-09 2012-08-16 Superlab Far East Limited Uses of recombinant super-compound interferons
EP1888633A4 (en) * 2005-05-18 2010-01-27 Maxygen Inc UNFOLDED INTERFERON ALPHA POLYPEPTIDE
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080014616A1 (en) * 2006-07-11 2008-01-17 Kevin Jarrell Methods of introducing targeted diversity into nucleic acid molecules
EP2042513A4 (en) * 2006-07-25 2010-07-07 Galpharma Co Ltd Galectin-9-POLYMER CONJUGATE
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
WO2009046080A1 (en) 2007-10-01 2009-04-09 Pharmaessentia Corp. N-terminal modified interferon-alpha
WO2009090056A2 (en) 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
CA2742988A1 (en) * 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US9944688B2 (en) 2011-06-02 2018-04-17 Hanmi Science Co., Ltd. Non-peptidyl polymer-insulin multimer and method for producing the same
CN103764665A (zh) 2011-06-28 2014-04-30 怀特黑德生物医学研究所 使用分选酶安装用于蛋白质连接的点击化学柄
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
BR112018010945A2 (pt) 2015-12-30 2018-12-04 Genentech Inc formulações com degradação de polissorbato reduzida
EP3411065B1 (en) * 2016-02-05 2021-03-31 Orionis Biosciences BV Clec9a binding agents
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
BR112022014567A2 (pt) * 2020-01-24 2022-09-27 Alkermes Pharma Ireland Ltd Métodos de purificação

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
EP0098876A1 (en) 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ATE174798T1 (de) 1990-10-17 1999-01-15 Amgen Inc Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
PT741577E (pt) 1994-03-07 2003-03-31 Imperial College Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
DE60035871T2 (de) 1999-05-19 2008-06-05 Merck Patent Gmbh Expression und export von interferon-alpha proteinen als fc fusionsproteine
WO2001025438A2 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
HUP0203409A3 (en) * 1999-11-12 2005-06-28 Maxygen Holdings Ltd Redwood C Interferon gamma conjugates
JP4873818B2 (ja) 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
CA2503594C (en) * 2002-11-15 2011-05-10 Doris Brugger Positional isomers of peg ifn alpha 2a
NZ540043A (en) * 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates

Also Published As

Publication number Publication date
EP1753779A2 (en) 2007-02-21
US7541163B2 (en) 2009-06-02
MXPA06013412A (es) 2007-01-23
NO20065084L (no) 2006-12-01
JP2008507298A (ja) 2008-03-13
US20080171363A1 (en) 2008-07-17
US20070020235A1 (en) 2007-01-25
US20070225205A1 (en) 2007-09-27
US20050266465A1 (en) 2005-12-01
CN101115769A (zh) 2008-01-30
US7531630B2 (en) 2009-05-12
US20080031853A1 (en) 2008-02-07
US20070025966A1 (en) 2007-02-01
US7537755B2 (en) 2009-05-26
US7531324B2 (en) 2009-05-12
IL178470A0 (en) 2007-02-11
WO2005113592A2 (en) 2005-12-01
WO2005113592A3 (en) 2006-04-06
US20070020734A1 (en) 2007-01-25
US20080076710A1 (en) 2008-03-27
CA2566247A1 (en) 2005-12-01
BRPI0511196A (pt) 2007-12-04
RU2006145020A (ru) 2008-06-27
AR049177A1 (es) 2006-07-05
US20070225204A1 (en) 2007-09-27
US7541436B2 (en) 2009-06-02
TW200611910A (en) 2006-04-16
US7318918B2 (en) 2008-01-15

Similar Documents

Publication Publication Date Title
US7541163B2 (en) Interferon-alpha polypeptides and conjugates
US7314613B2 (en) Interferon-alpha polypeptides and conjugates
US7619067B2 (en) Evolved interferon-alpha polypeptides
AU2003297285A1 (en) Interferon-alpha polypeptides and conjugates
ZA200503782B (en) Interferon-alpha polypeptides and conjugates
KR20070022279A (ko) 인터페론-알파 폴리펩티드 및 컨쥬게이트

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period